Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 3/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | CFTR | P13569 | 1/20 | 0.68 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417334 | 1.00 | ALDH1A1 (0.71) | ALDH1A1KDM4EHPGDHSD17B10CFTR | |
| SCHEMBL11841438 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDHSD17B10CFTR | |
| SCHEMBL1722083 | 0.83 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDHSD17B10CFTR | |
| SCHEMBL165304 | 0.83 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10CFTR | |
| SCHEMBL955863 | 0.83 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CFTR | |
| SCHEMBL21852902 | 0.82 | CES2 (0.55) | ALDH1A1KDM4EHPGDHSD17B10CFTR | |
| SCHEMBL24137114 | 0.81 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10CFTR | |
| SCHEMBL18534932 | 0.81 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDHSD17B10CFTR | |
| SCHEMBL18291815 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDHSD17B10CFTR | |
| SCHEMBL1451351 | 0.81 | CFTR (1.00) | ALDH1A1KDM4EHPGDHSD17B10CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144399-A1 | QUINOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220388969-A1 | SUBSTITUTED 3,4-DIHYDROQUINAZOLINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220348549-A1 | QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-11-03 | — | — | US | disclosed |
| EP-4038055-A1 | SUBSTITUTED 3,4-DIHYDROQUINAZOLINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2022-08-10 | — | — | EP | disclosed |
| EP-4021895-A1 | NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| EP-4021441-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | Trustees of Dartmouth College (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021063856-A1 | SUBSTITUTED 3,4-DIHYDROQUINAZOLINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021042046-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021042046-A1 | MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021037868-A1 | NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-04 | — | — | WO | disclosed |
| US-7312248-B2 | Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007116314-A1 | N-PHENYL-1,1,1-TRIFLUOROMETHANESULFONAMIDE HYDRAZONE DERIVATIVE COMPOUNDS AND THEIR USAGE IN CONTROLLING PARASITES | SCHERING-PLOUGH LTD. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070238700-A1 | N-PHENYL-1,1,1-TRIFLUOROMETHANESULFONAMIDE HYDRAZONE DERIVATIVE COMPOUNDS AND THEIR USAGE IN CONTROLLING PARASITES | SCHERING-PLOUGH LTD. (CH) | 2007-10-11 | — | — | US | disclosed |
| EP-1799636-A2 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES | Schering-Plough Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006034333-A2 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES | SCHERING-PLOUGH LTD. (CH) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063841-A1 | Parasiticides; nematocides; crop protection | SCHERING-PLOUGH LTD. (CH) | 2006-03-23 | — | — | US | disclosed |
| US-5214059-A | Dermatitis, psoriasis | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-05-25 | — | — | US | disclosed |
| US-5166170-A | 2-(AMINOARYL) INDOLES AND INDOLINES AS TOPICAL ANTIINFLAMMATORY AGENTS FOR THE TREATMENT OF SKIN DISORDERS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-11-24 | — | — | US | disclosed |
| EP-0406734-A2 | 2-(Aminoaryl)indoles and indolines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-01-09 | — | — | EP | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063841-A1 | Parasiticides; nematocides; crop protection | TRHDE, DDT, EPHX1 | ALDH1A1 4339/4885KDM4E 403/4885HPGD 1936/4885 |
| US-20230144399-A1 | QUINOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | RECQL, SLC10A1, UGT1A1 | ALDH1A1 405/4885KDM4E 2574/4885HPGD 1224/4885 |
| US-20070238700-A1 | N-PHENYL-1,1,1-TRIFLUOROMETHANESULFONAMIDE HYDRAZONE DERIVATIVE COMPOUNDS AND THEIR USAGE IN CONTROLLING PARASITES | NAT1, NGLY1, ELANE | ALDH1A1 894/4885KDM4E 1150/4885HPGD 1426/4885 |
| US-20220348549-A1 | QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HAVCR2, RECQL, SLC10A1 | ALDH1A1 713/4885KDM4E 2808/4885HPGD 1254/4885 |
| US-20220388969-A1 | SUBSTITUTED 3,4-DIHYDROQUINAZOLINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP3A43, CYP2F1 | ALDH1A1 238/4885KDM4E 1655/4885HPGD 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.